These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 20212254)

  • 1. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
    Ravandi F; Cortes JE; Jones D; Faderl S; Garcia-Manero G; Konopleva MY; O'Brien S; Estrov Z; Borthakur G; Thomas D; Pierce SR; Brandt M; Byrd A; Bekele BN; Pratz K; Luthra R; Levis M; Andreeff M; Kantarjian HM
    J Clin Oncol; 2010 Apr; 28(11):1856-62. PubMed ID: 20212254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.
    Al-Kali A; Cortes J; Faderl S; Jones D; Abril C; Pierce S; Brandt M; Kantarjian H; Ravandi F
    Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):361-6. PubMed ID: 21816375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
    Inaba H; Rubnitz JE; Coustan-Smith E; Li L; Furmanski BD; Mascara GP; Heym KM; Christensen R; Onciu M; Shurtleff SA; Pounds SB; Pui CH; Ribeiro RC; Campana D; Baker SD
    J Clin Oncol; 2011 Aug; 29(24):3293-300. PubMed ID: 21768474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
    Ravandi F; Alattar ML; Grunwald MR; Rudek MA; Rajkhowa T; Richie MA; Pierce S; Daver N; Garcia-Manero G; Faderl S; Nazha A; Konopleva M; Borthakur G; Burger J; Kadia T; Dellasala S; Andreeff M; Cortes J; Kantarjian H; Levis M
    Blood; 2013 Jun; 121(23):4655-62. PubMed ID: 23613521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
    Sharma M; Ravandi F; Bayraktar UD; Chiattone A; Bashir Q; Giralt S; Chen J; Qazilbash M; Kebriaei P; Konopleva M; Andreeff M; Cortes J; McCue D; Kantarjian H; Champlin RE; de Lima M
    Biol Blood Marrow Transplant; 2011 Dec; 17(12):1874-7. PubMed ID: 21767516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib.
    Yalniz F; Abou Dalle I; Kantarjian H; Borthakur G; Kadia T; Patel K; Loghavi S; Garcia-Manero G; Sasaki K; Daver N; DiNardo C; Pemmaraju N; Short NJ; Yilmaz M; Bose P; Naqvi K; Pierce S; Nogueras González GM; Konopleva M; Andreeff M; Cortes J; Ravandi F
    Am J Hematol; 2019 Sep; 94(9):984-991. PubMed ID: 31237017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation.
    Giri S; Hamdeh S; Bhatt VR; Schwarz JK
    J Natl Compr Canc Netw; 2015 May; 13(5):508-14. PubMed ID: 25964636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Erba HP; Montesinos P; Kim HJ; Patkowska E; Vrhovac R; Žák P; Wang PN; Mitov T; Hanyok J; Kamel YM; Rohrbach JEC; Liu L; Benzohra A; Lesegretain A; Cortes J; Perl AE; Sekeres MA; Dombret H; Amadori S; Wang J; Levis MJ; Schlenk RF;
    Lancet; 2023 May; 401(10388):1571-1583. PubMed ID: 37116523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
    Man CH; Fung TK; Ho C; Han HH; Chow HC; Ma AC; Choi WW; Lok S; Cheung AM; Eaves C; Kwong YL; Leung AY
    Blood; 2012 May; 119(22):5133-43. PubMed ID: 22368270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML.
    Wang ES; Goldberg AD; Tallman M; Walter RB; Karanes C; Sandhu K; Vigil CE; Collins R; Jain V; Stone RM
    J Clin Oncol; 2024 May; 42(15):1776-1787. PubMed ID: 38324741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
    Kadia TM; Reville PK; Borthakur G; Yilmaz M; Kornblau S; Alvarado Y; Dinardo CD; Daver N; Jain N; Pemmaraju N; Short N; Wang SA; Tidwell RSS; Islam R; Konopleva M; Garcia-Manero G; Ravandi F; Kantarjian HM
    Lancet Haematol; 2021 Aug; 8(8):e552-e561. PubMed ID: 34329576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186.
    Macdonald DA; Assouline SE; Brandwein J; Kamel-Reid S; Eisenhauer EA; Couban S; Caplan S; Foo A; Walsh W; Leber B
    Leuk Lymphoma; 2013 Apr; 54(4):760-6. PubMed ID: 23061485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.
    Kadia TM; Ravandi F; Molica M; Bataller A; Borthakur G; Daver N; Jabbour E; DiNardo CD; Pemmaraju N; Jain N; Ferrajoli A; Ylimaz M; Bose P; Tidwell RS; Marx KR; Rausch CR; Kanagal-Shamanna R; Wang S; Islam R; Champlin R; Shpall E; Konopleva M; Garcia-Manero G; Kantarjian H
    Am J Hematol; 2023 Nov; 98(11):1711-1720. PubMed ID: 37635400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients.
    Borthakur G; Zeng Z; Cortes JE; Chen HC; Huang X; Konopleva M; Ravandi F; Kadia T; Patel KP; Daver N; Kelly MA; McQueen T; Wang RY; Kantarjian H; Andreeff M
    Am J Hematol; 2020 Nov; 95(11):1296-1303. PubMed ID: 32697348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.
    Baker SD; Zimmerman EI; Wang YD; Orwick S; Zatechka DS; Buaboonnam J; Neale GA; Olsen SR; Enemark EJ; Shurtleff S; Rubnitz JE; Mullighan CG; Inaba H
    Clin Cancer Res; 2013 Oct; 19(20):5758-68. PubMed ID: 23969938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Jabbour E; Kantarjian H; Ravandi F; Garcia-Manero G; Estrov Z; Verstovsek S; O'Brien S; Faderl S; Thomas DA; Wright JJ; Cortes J
    Cancer; 2011 Mar; 117(6):1236-44. PubMed ID: 20960519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
    Zhang C; Lam SSY; Leung GMK; Tsui SP; Yang N; Ng NKL; Ip HW; Au CH; Chan TL; Ma ESK; Yip SF; Lee HKK; Lau JSM; Luk TH; Li W; Kwong YL; Leung AYH
    Cancer; 2020 Jan; 126(2):344-353. PubMed ID: 31580501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.
    Battipaglia G; Ruggeri A; Massoud R; El Cheikh J; Jestin M; Antar A; Ahmed SO; Rasheed W; Shaheen M; Belhocine R; Brissot E; Dulery R; Eder S; Giannotti F; Isnard F; Lapusan S; Rubio MT; Vekhoff A; Aljurf M; Legrand O; Mohty M; Bazarbachi A
    Cancer; 2017 Aug; 123(15):2867-2874. PubMed ID: 28387928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.
    Cortes JE; Khaled S; Martinelli G; Perl AE; Ganguly S; Russell N; Krämer A; Dombret H; Hogge D; Jonas BA; Leung AY; Mehta P; Montesinos P; Radsak M; Sica S; Arunachalam M; Holmes M; Kobayashi K; Namuyinga R; Ge N; Yver A; Zhang Y; Levis MJ
    Lancet Oncol; 2019 Jul; 20(7):984-997. PubMed ID: 31175001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
    Hu S; Niu H; Inaba H; Orwick S; Rose C; Panetta JC; Yang S; Pounds S; Fan Y; Calabrese C; Rehg JE; Campana D; Rubnitz JE; Baker SD
    J Natl Cancer Inst; 2011 Jun; 103(11):893-905. PubMed ID: 21487100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.